All In Biotech

Drug Trial Radar · NCT05562609

Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk

Tranexamic Acid by the Intramuscular or Intravenous Route for the Prevention of Postpartum Haemorrhage in Women at Increased Risk: a Randomised, Double-blind, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 40,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

40,000

Planned (sponsor's estimate)

Start

Apr 22, 2024

Primary completion

Sep 2027

Study completion Oct 2027

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UNITAID
First posted
Oct 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Heavy bleeding after childbirth, known as a postpartum haemorrhage (PPH), causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a lifesaving treatment for women with PPH. The I'M WOMAN trial is a research study to see whether giving TXA just before childbirth will stop women developing PPH. The trial will assess the effects of intramuscular (IM) and intravenous (IV) tranexamic acid on PPH, side effects and other important maternal health outcomes.

Conditions

  • Postpartum Hemorrhage

Interventions

  • Tranexamic acidDrug

    Ampoules and packaging for all arms will be identical in appearance.

  • PlaceboOther

    Ampoules and packaging for all arms will be identical in appearance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Risk of Postpartum haemorrhageTime frame: within 24 hours of childbirth

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mbeya Regional Referral Hospital

    Mbeya, Tanzania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.